United Therapeutics gets crucial green light for its flagship drug

Key story highlights: United Therapeutics Corp. has received Food and Drug Administration approval for an implantable pump for Remodulin, its flagship pulmonary arterial hypertension drug. The approval means the Silver Spring drugmaker, contending with expiring drug patents, could maintain an edge over generic competit ion. United Therapeutics also inches forward with its acquisition of Israel-based SteadyMed Therapeutics Inc. — expected to close in the third quarter. United Therapeutics Corp.…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news